기업
BMS
주관 임상 199건 · 진행 중 450건 · FDA 승인 2건
주관 임상 단계 분포
관련 뉴스
전체 뉴스 →신약개발2026-07-14
휴야바이오, HBI-8000과 옵디보 병용요법 피부암 3상서 '이정표' 달성
휴야바이오는 경구용 히스톤탈아세틸화효소(HDAC) 억제제 HBI-8000과 브리스톨마이어스스큅(BMS)의 옵디보(니볼루맙) 병용요법이 진행성 피부암 환자를 대상으로 한 3상 임상시험에서 성공적인 결과를 얻었다고 밝혔다. 이번 임상은 회사 설립 22년 만에 진행한 최대 규모의 항암 연구로 평가된다. 구체적인 임상 수치나 통계적 유의성에 대한 세부 내용은 원문에 명시되지 않았다. 해당 병용요법이 어떤 평가변수를 충족했는지에 대한 추가 정보는 확인되지 않았다.
Fierce Pharma ↗
FDA 승인
진행 중인 임상
- 3상모집 예정협력· Schizophrenia; Psychosis
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCT07084831 - 3상모집 예정· Pulmonary Fibrosis
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408 - 4상모집 예정· Untreated Melanoma
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
NCT07459543 - 해당없음모집 예정협력· Lung Carcinoma
An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial
NCT07615764 - 2상모집 예정협력· Lymphoma
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
NCT07711483 - 3상모집 예정· Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790 - 1/2상모집 예정· Arthritis, Rheumatoid
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704 - 3상모집 예정· Irritability Associated With Autism Spectrum Disorder
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798 - 3상모집 예정· Irritability Associated With Autism Spectrum Disorder
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745 - 3상모집 예정협력· Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 - 1상모집 예정협력· AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
NCT07573332 - 2상모집 예정· Chronic Immune Thrombocytopenia
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557 - 3상모집 중· Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562 - 2상모집 예정· Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764 - 4상모집 예정협력· Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
NCT07681076 - 2상모집 예정· Solid Tumors
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 - 1상모집 예정협력· KMT2A-rearranged
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
NCT07355335 - 1/2상모집 중협력· Antineutrophil Cytoplasmic Antibody-associated Vasculitis
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
NCT07388277 - 1/2상모집 중협력· SCHIZOPHRENIA 1 (Disorder)
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07423546 - 단계 미표기모집 예정협력· Lung Cancer
AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk
NCT07553598
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.